Effects of Ala-Gln dipeptide parenteral nutrition on rehabilitation and infection of liver transplantation patients

This study aimed to explore the application and effect of alanyl-glutamine (Ala-Gln) dipeptide parenteral nutrition support in liver transplantation patients. A randomized controlled trial was performed, including and analyzing 96 patients who underwent liver transplantation surgery in our hospital from March 2019 to February 2023. These 96 patients were randomly divided into an experimental group and a control group, with 48 cases in each group. The control group was supplied with branched-chain amino acids (BCAAs) as a nitrogen source, and the experimental group was supplied with BCAAs + Ala-Gln. The results indicated that the levels of prealbumin (PA), serum albumin (ALB), and transferrin (TRF) in the experimental group were higher than those in the control group (P<0.05). The duration of care at the intensive care unit (ICU) and hospitalization of the experimental group were shorter than the control group (P<0.05). The incidence of infection events of the experimental group was lower than that in the control group (P<0.05). Collectively, the use of Ala-Gln in parenteral nutrition support for liver transplantation patients can significantly improve the nutritional status of the body, shorten the length of hospitalization time and reduce the incidence of infection.